Management of mCRPC patients treated with 223Radium-dicloride in the scenario of the COVID-19 outbreak

Coronavirus-2019-disease(COVID-19), reported as cause of global public health emergency, recently launched its aura of fear around the world. Many countries have adopted restrictive measures for spread of the infection, which range from isolating the population at home to the closure of work activities. In this scenario, hospitals also had to review patient entry and care policies. However, primary emergency care and treatment of cancer patients are guaranteed. Among these, an important part is those with prostate cancer, second leading cause of death worldwide. There are many therapies that these patients can do, manageable from home for patients not yet resistant to castration, more difficult to manage if resistance has already occurred or if there are metastases and pain. In fact, systemic therapies for metastatic castration-resistant prostate cancer(mCRPC) include the use Radium-223-dichloride(223Ra), which can only be administered in a hospital setting.